Oct 30 (Reuters) - AstraZeneca Plc said on Friday it had agreed to sell commercial rights for two of its heart failure and blood pressure medicines to German pharmaceutical company Cheplapharm Arzneimittel GmbH for $400 million.
Under the deal, Cheplapharm will get commercial rights for Atacand and Atacand Plus in around 70 countries globally, AstraZeneca said.
Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Sriraj Kalluvila
Our Standards: The Thomson Reuters Trust Principles.